CME
Latest Episodes
Demystifying Continued Pharmacologic Therapy in HFrEF – Pivotal Opportunities to Improve Patient Outcomes
Host: Ileana L. Piña, MD, MPH, FAHA, FACC Guest: Javed Butler, MD, MBA, MPH Guest: Gregg C. Fonarow, MD Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA Recent guideline updates and publications are leading to changes in care in patients with h
Evolving Pharmacologic Intervention for Methamphetamine Use Disorder: A Focus on ADAPT-2
Guest: Madhukar H. Trivedi, MD Guest: Steven Shoptaw, PhD Join Drs. Madhukar Trivedi and Steven Shoptaw as they discuss the evolving landscape of pharmacologic intervention for methamphetamine use disorder. Their focus will be on evidence from the
A New Normal? COVID-19 and HF in Clinical Trials
Host: Javed Butler, MD, MBA, MPH Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC The COVID-19 pandemic has had an unprecedented impact on the entire global population. COVID-19 fears have
Hot Topics in HCV: A Multidisciplinary Online Minicurriculum: Activity 1: Treating Hepatitis C in Primary Care? You Can! You Should!
Host: Ricardo Franco, MD Guest: Charles P. Vega, MD Armed with Centers for Disease Control and Prevention (CDC) guidelines for HCV universal screening and risk-based testing — and an understanding of the simplicity of prescribing and managing direc
RCC Treatment Strategies in a Favorable-Risk Patient
Host: Jay Raman, MD, FACS Guest: Oguz Akin, MD Guest: Robert J. Motzer, MD Guest: Elizabeth Plimack, MD, MS Immune checkpoint inhibitor/tyrosine kinase inhibitor combination therapy has forged to the front-line for the management of metastatic
A New Normal? COVID-19 and HF in Clinical Trials
Host: Javed Butler, MD, MBA, MPH Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC The COVID-19 pandemic has had an unprecedented impact on the entire global population. COVID-19 fears have
The Itch Clinic: Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients
Guest: Steven Fishbane, MD Guest: Shayan Shirazian, MD Host: Jennifer Caudle, DO At least 25% of patients with chronic kidney disease (CKD) and between 50% to 86% of patients with CKD on dialysis suffer from CKD-associated pruritus (CKD-aP). The
State of the Union: Advances in the Management of mUC
Host: Arjun V. Balar, MD Guest: Daniel P. Petrylak, MD Bladder cancer is the sixth most common malignancy in the United States. Many of these patients present with multiple comorbidities which creates a considerable challenge for clinicians when de
FIGARO-DKD and FIDELITY Analysis: Key Takeaways
Host: George L. Bakris, MD Guest: Rajiv Agarwal, MBBS, MD, FASN, BRCU Guest: Bertram Pit, MD Two HOT LINE sessions presented at the ESC Congress 2021 may change the way you manage your patients with diabetes and CKD as you work to prevent their p
Optimizing the Care and Quality of Life for Patients with ADPKD – Part 4: Emerging Therapies
Guest: Arlene B. Chapman, MD Guest: Michel Chonchol, MD This Expert Exchange webcast aims to improve clinicians’ awareness of emerging agents in the treatment of patients with ADPKD.